BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38637099)

  • 1. Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis.
    Sahraoui G; Rahoui N; Driss M; Mrad K
    Int Rev Cell Mol Biol; 2024; 384():47-61. PubMed ID: 38637099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological and molecular characteristics of inflammatory breast cancer.
    Di Bonito M; Cantile M; Botti G
    Transl Cancer Res; 2019 Oct; 8(Suppl 5):S449-S456. PubMed ID: 35117122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling and characterization of inflammatory breast cancer emboli grown in vitro.
    Lehman HL; Dashner EJ; Lucey M; Vermeulen P; Dirix L; Van Laere S; van Golen KL
    Int J Cancer; 2013 May; 132(10):2283-94. PubMed ID: 23129218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
    Provance OK; Lewis-Wambi J
    Breast Cancer Res; 2019 May; 21(1):59. PubMed ID: 31060575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.
    Valeta-Magara A; Gadi A; Volta V; Walters B; Arju R; Giashuddin S; Zhong H; Schneider RJ
    Cancer Res; 2019 Jul; 79(13):3360-3371. PubMed ID: 31043378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.
    Levine PH; Portera CC; Hoffman HJ; Yang SX; Takikita M; Duong QN; Hewitt SM; Swain SM
    Clin Breast Cancer; 2012 Aug; 12(4):232-9. PubMed ID: 22694825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory breast cancer biology: the tumour microenvironment is key.
    Lim B; Woodward WA; Wang X; Reuben JM; Ueno NT
    Nat Rev Cancer; 2018 Aug; 18(8):485-499. PubMed ID: 29703913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent E-cadherin expression in inflammatory breast cancer.
    Kleer CG; van Golen KL; Braun T; Merajver SD
    Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.
    Mohamed MM; El-Ghonaimy EA; Nouh MA; Schneider RJ; Sloane BF; El-Shinawi M
    Int J Biochem Cell Biol; 2014 Jan; 46():138-47. PubMed ID: 24291763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MARCKS protein overexpression in inflammatory breast cancer.
    Manai M; Thomassin-Piana J; Gamoudi A; Finetti P; Lopez M; Eghozzi R; Ayadi S; Lamine OB; Manai M; Rahal K; Charafe-Jauffret E; Jacquemier J; Viens P; Birnbaum D; Boussen H; Chaffanet M; Bertucci F
    Oncotarget; 2017 Jan; 8(4):6246-6257. PubMed ID: 28009981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer.
    Rogic A; Pant I; Grumolato L; Fernandez-Rodriguez R; Edwards A; Das S; Sun A; Yao S; Qiao R; Jaffer S; Sachidanandam R; Akturk G; Karlic R; Skobe M; Aaronson SA
    Nat Commun; 2021 Nov; 12(1):6889. PubMed ID: 34824220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
    Iwamoto T; Bianchini G; Qi Y; Cristofanilli M; Lucci A; Woodward WA; Reuben JM; Matsuoka J; Gong Y; Krishnamurthy S; Valero V; Hortobagyi GN; Robertson F; Symmans WF; Pusztai L; Ueno NT
    Breast Cancer Res Treat; 2011 Feb; 125(3):785-95. PubMed ID: 21153052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of inflammatory and non-inflammatory locally advanced breast cancer - the experience of a Moroccan hospital].
    Benbrahim Z; Berrada A; Amaadour L; Zahra El M'rabet F; Elfatemi H; Elfakir S; Mellas N; Arifi S
    Gynecol Obstet Fertil Senol; 2017 Nov; 45(11):604-608. PubMed ID: 29100820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
    Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
    Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.